Zymeworks(ZYME)

Zymeworks Presents New Preclinical Data at AACR 2026 - GlobeNewswire

Zymeworks Presents New Preclinical Data at AACR 2026  GlobeNewswire

Zymeworks announces leadership appointments - The Pharma Letter

Zymeworks announces leadership appointments  The Pharma Letter

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate - GlobeNewswire

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate  GlobeNewswire

FDA speeds review of Zymeworks ovarian cancer drug ZW191 - Stock Titan

FDA speeds review of Zymeworks ovarian cancer drug ZW191  Stock Titan

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate - GlobeNewswire

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate  GlobeNewswire

Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials - Clinical Leader

Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials  Clinical Leader